December 12: The Week in Cancer News
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Progress Against Cancer
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with BRCA1/2 mutations.
SABCS educational session highlights how alcohol and obesity can raise the risk for breast cancer.
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent AACR conferences.
Research continues to show efficacy of HPV vaccines at preventing cervical cancer, and the FDA approves an immunotherapy for use before and after surgery for stomach cancers.
The inaugural AACR Pediatric Cancer Progress Report details advances in treating children and adolescents with cancer and remaining gaps in care.
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma (MZL)...
Pirtobrutinib was approved for certain relapsed/refractory chronic lymphocytic leukemias or small lymphocytic lymphomas. The U.S. Food and Drug Administration (FDA) has granted traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory chronic...
Durvalumab was approved as neoadjuvant and adjuvant treatment with chemotherapy for resectable gastric or gastroesophageal junction cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) as a neoadjuvant and adjuvant therapy...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More